What do we do for the patient who have tried everything to treat their ocular surface disease? As testing for dry eye evolves to understand the underlying causes better, our treatments also continue to improve. We will discuss new and emerging ocular surface disease treatments and who may benefit.
Almost 1000 attended our event and we received amazing feedback!
Feedback from anonymous survey:
Excellent lecture! Thank you for the new treatment options!
Wonderful info on updates in dry eye treatments.
Super helpful to have all the new therapies together in a single review so I may orient myself to either implement or further research! Thank you!
I can tell Dr. Cecelia Koetting is very passionate and excited about what she lectured on.
Excellent new Rx therapies for DED.
I enjoyed learning about the new treatments that aren't FDA approved yet.
So much new and interesting OSD tx’s. Please have more hours on individual txs esp ones in phase 3.
Speaker: Dr. Cecelia Koetting
Moderator: Dr. Elise Kramer
COPE ID: 91577-TD
Category: Trt/Mngmnt Ocular Disease
This event is COPE approved for 1 hour of CE credit.
Thank you to Thea Pharma for exhibiting at this event.